We turn discovery into action, advancing differentiated small molecule medicines through in-house expertise and strategic partnerships. Our therapies aim to address serious conditions where patients are underserved by existing treatments.

Squiggle Graphic
LATEST NEWS
July 1, 2025
Tay Therapeutics launches a new spin-out: Hawkhill Therapeutics
June 11, 2025
Tay Therapeutics featured in European Biopharmaceutical Review
February 24, 2025
Tay Therapeutics Strengthens BET Asset Portfolio with Key IP Assignment from Dundee University